Vacunación de COVID-19 en grupos ginecológicos y obstétricos especiales

María Antonia López Rubio

doi:10.19230/jonnpr.4187

Autores/as

María Antonia López Rubio Ginecóloga. Complejo Hospitalario Universitario de Albacete (SESCAM). España

DOI:

https://doi.org/10.19230/jonnpr.4187

Palabras clave:

COVID-19, coronavirus, embarazo, lactancia, vacuna, pandemia, cáncer ginecológico

Resumen

La pandemia por COVID-19 y las serias repercusiones que está teniendo han hecho que se agilice el desarrollo de un arma terapéutica fundamental para comenzar a erradicarla: las vacunas. Son un instrumento fundamental de prevención primaria que se administrará inicialmente a los grupos más vulnerables o con alto riesgo de exposición, ampliando el abanico de administración a otro tipo de población en fases posteriores. Puede surgir controversia a la hora de vacunar a grupos ginecológicos específicos, como son las gestantes, mujeres lactantes o pacientes con cáncer ginecológico. El propósito de este artículo es analizar la información disponible con respecto a la vacunación en estos grupos.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

María Antonia López Rubio, Ginecóloga. Complejo Hospitalario Universitario de Albacete (SESCAM). España

Médico Especialista en Medicina Familiar y Comunitaria.

Doctora en Cirugía por la Universidad Autónoma de Madrid.

M.I.R. en Obstetricia y Ginecologçía

Citas

Líneas maestras para la vacunación de COVID19 en España. Disponible online en: https://www.mscbs.gob.es/gabinetePrensa/notaPrensa/pdf/24.11241120144431769.pdf

Di Mascio D, Khalil A, Saccone G. Outcome of coronavirus spectrum infections (SARS, MERS, COVID 1-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020. Published online.

López Rubio MA. Born in the time of COVID-19. JONNPR. 2020;5(6):597-602.

Preguntas y respuestas sobre la vacunación de Covid 19. Disponible online en: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/VACUNACION-COVID-19_PREGUNTAS.pdf

Rasmussen SA, Kelley CF, Horton JP, Jamieson DJ. Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: What Obstetricians Need to Know. Obstet Gynecol. 2020; Publish Ahead of Print.

Whitehead CL, Walker SP. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials. Lancet. 2020;395 (10237):e92.

Heath PT, Le Doare K, Khalil A. Inclusion of pregnant women in COVID-19 vaccine development. Lancet Infect Dis. 2020;20:1007-1008.

Costantine MM, Landon MB, Saade GR. Protection by Exclusion: Another Missed Opportunity to Include Pregnant Women in Research During the Coronavirus Disease 2019 (COVID-19) Pandemic. Obstet Gynecol. 2020;136:26-28.

COVID-19 vaccines. Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006–2020

Anderson PO. Maternal vaccination and breastfeeding. Breastfeed Med. 2019;14:215–217.

American College of Obstetricians and Gynecologists. Practice Advisory. Vaccinating pregnant and lactating patients against COVID-19. December 13, 2020. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-covid-19

Academy of Breastfeeding Medicine (ABM) statement: Considerations for COVID-19 vaccination in lactation. December 14, 2020. https://abm.memberclicks.net/abm-statement-considerations-for-covid-19-vaccination-in-lactation?fbclid=IwAR0LC26lCj_pJmpIHMa5QGdq9V8bN5XQsdIBYSyTXoYJMwqEP4SJIV2k5xw.

Society for Maternal Fetal Medicine. Experts in high-risk pregnancy respond to the FDA’s decision to offer the newly approved COVID-19 vaccine to pregnant and lactating people. December 11, 2020. https://s3.amazonaws.com/cdn.smfm.org/media/2632/FDA_final.pdf.

Society for Maternal Fetal Medicine. SMFM: Provider considerations for engaging in COVID-19 vaccine counseling with pregnant and lactating patients. December 15, 2020. https://s3.amazonaws.com/cdn.smfm.org/media/2641/Provider_Considerations_for_Engaging_in_COVID_Vaccination_Considerations_12-15-20_(final).pdf.

Le TK, Paris C, Khan KS, et al. Nucleic acid-based technologies targeting coronaviruses. Trends Biochem Sci. 2020

Pace RM, Williams JE, Järvinen KM, et al. COVID-19 and human milk: SARS-CoV-2, antibodies, and neutralizing capacity. medRxiv 2020.

Madan A, Siglin J, Khan A. Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic. Cancer Med. 2020;9:9205-9218.

Sidaway, P. COVID-19 and cancer: what we know so far. Nat Rev Clin Oncol 17, 336 (2020).

R. Bitterman, N. Eliakim‐Raz, I. Vinograd, A.Z. Trestioreanu, L. Leibovici, M. Paul, Influenza vaccines in immunosuppressed adults with cancer, Cochrane Database Syst. Rev. 2018.

L. Zhang, F. Zhu, L. Xie, C. Wang, J. Wang, R. Chen, P. Jia, H. Guan, L. Peng, Y. Chen, Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals in three hospitals within Wuhan, China, Ann. Oncol. 2020; S0923-7534 (20) 36383–36393.

Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S. COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. Int Immunopharmacol. 2020;90:107247.